We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Proteome Sciences Plc | LSE:PRM | London | Ordinary Share | GB0003104196 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.64 | 18.23% | 4.15 | 3.50 | 4.80 | 423,867 | 16:35:28 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 7.78M | 1.33M | 0.0045 | 7.80 | 10.36M |
TIDMPRM
RNS Number : 1111C
Proteome Sciences PLC
11 April 2017
Proteome Sciences plc
(the "Company" or the "Group")
Director Dealing and Total Voting Rights
Proteome Sciences plc (AIM:PRM) announces that on 7 April 2017, Ian Pike, Chief Scientific Officer of the Company and a former employee exercised 165,583 and 158,308 options over ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") respectively.
Application has been made to the London Stock Exchange for the 323,891 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 18 April 2017.
After Admission, the total number of Ordinary Shares in issue will be 294,648,723, all with voting rights. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
For further information: Proteome Sciences plc Dr Jeremy Haigh, Chief Executive Officer Tel: +44 (0)1932 865065 Dr Ian Pike, Chief Scientific Officer Geoff Ellis, Finance Director finnCap Limited (Nominated Adviser/Broker) Tel: +44 (0)20 7220 Geoff Nash/James Thompson 0500 Tony Quirke (broking) IFC Advisory (Financial PR and IR) Tim Metcalfe/Graham Tel: +44 (0)20 3053 Herring/Miles Nolan 8671
Notes for editors:
Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant(R) , TMTcalibrator(TM) ) and for the discovery, validation and assay development of protein biomarkers. The company has its headquarters in Cobham, UK, with laboratory facilities in London, UK and in Frankfurt, Germany from where the PS Biomarker Services(TM) division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.
Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.
This announcement contains inside information for the purpose of Article 7 of EU Regulation 596/2014.
1. Details of the person discharging managerial responsibilities / person closely associated a) Name Ian Pike 2. Reason for the Notification a) Position/status Chief Scientific Officer b) Initial notification/Amendment Initial notification 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Proteome Sciences plc b) LEI n/a 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the Financial instrument, type of Options over Ordinary Shares of 1p each instrument Identification code GB0003104196 b) Nature of the transaction Exercise of options c) Price(s) and volume(s) 165,583 options d) Aggregated information: -- Aggregated volume 165,583 Options over Ordinary Shares of 1p each -- Price exercised e) Date of the transaction 7 April 2017 f) Place of the transaction London Stock Exchange, AIM Market (XLON)
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFMGMDKGZGNZM
(END) Dow Jones Newswires
April 11, 2017 02:00 ET (06:00 GMT)
1 Year Proteome Sciences Chart |
1 Month Proteome Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions